Oculis to Participate at Upcoming Investor Conferences
April 05, 2023 07:00 ET
|
Oculis SA
ZUG, Switzerland and BOSTON, April 05, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones
April 04, 2023 07:00 ET
|
Oculis SA
ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care,...
Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing
March 22, 2023 07:00 ET
|
Oculis SA
ZUG, Switzerland, and BOSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye...
Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial
March 16, 2023 09:45 ET
|
Oculis SA
Completed enrollment in Phase 3 OPTIMIZE trial brings OCS-01 one step further on the regulatory path to approval.If approved, OCS-01 has the potential to become the first once-daily, topical,...
Oculis establishes presence in U.S. and appoints Sylvia Cheung as Chief Financial Officer
September 01, 2020 08:00 ET
|
Oculis SA
LAUSANNE, Switzerland, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a biopharmaceutical company focused on developing transformative topical ophthalmic treatments to improve the sight and lives...
Oculis Appoints Dr. Frédéric Pilotaz as Vice President of Technology & Pharmaceutical Sciences
April 21, 2020 08:00 ET
|
Oculis SA
LAUSANNE, Switzerland, April 21, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic...
Oculis Appoints Marcia de Souza Lima, M.D., as Chief Medical Officer
March 03, 2020 08:00 ET
|
Oculis SA
LAUSANNE, Switzerland, March 03, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic...
Oculis Announces Positive OCS-01 Phase 2 Data in Patients with Diabetic Macular Edema (DME)
February 10, 2020 08:00 ET
|
Oculis SA
OCS-01 is a proprietary topical nanoparticle formulation of dexamethasone that has the potential to treat retinal diseases The Phase 2 (DX-211) study provides a clinical proof-of-concept of OCS-01...
Oculis Announces Upcoming Presentation of Phase 2 Data of OCS-01 in Patients with Diabetic Macular Edema (DME) at Angiogenesis, Exudation, and Degeneration 2020
January 22, 2020 08:00 ET
|
Oculis SA
LAUSANNE, Switzerland, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Oculis S.A., a clinical-stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic...
Oculis Announces Dosing of First Patient in Randomized Phase 2b (SKYGGN) Clinical Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery
October 07, 2019 08:00 ET
|
Oculis SA
OCS-01 is a proprietary topical nanoparticle formulation of dexamethasone also in a Phase 2b trial for diabetic macular edema (DME) LAUSANNE, Switzerland, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Oculis...